You have accessJournal of UrologyUrodynamics/Incontinence/Female Urology: Incontinence Therapy I1 Apr 2014MP33-17 CONTEMPORARY COMPARISON BETWEEN RETROPUBIC MID URETHRAL SLING (MUS) AND AUTOLOGOUS PUBOVAGINAL SLING (PVS) FOR STRESS URINARY INCONTINENCE (SUI) AFTER THE FDA ADVISORY WARNING Stephen Mock, Jonathan Angelle, W. Stuart Reynolds, David J. Osborn, Roger R. Dmochowski, and Alexander Gomelsky Stephen MockStephen Mock More articles by this author , Jonathan AngelleJonathan Angelle More articles by this author , W. Stuart ReynoldsW. Stuart Reynolds More articles by this author , David J. OsbornDavid J. Osborn More articles by this author , Roger R. DmochowskiRoger R. Dmochowski More articles by this author , and Alexander GomelskyAlexander Gomelsky More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.968AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES At present, synthetic MUS is widely considered to be the standard of care for female SUI and has largely replaced the PVS, a traditionally more morbid procedure. In light of the 2011 FDA warning on mesh use for pelvic organ prolapse (POP), concerns regarding mesh use, in general, have been raised by both patients and providers. As a result, fewer patients may be opting for mesh. The aim of this study is to compare efficacy and complication rates in a cohort of women who were offered either procedure after the FDA warning and made an informed decision on procedure option. METHODS A total of 201 women underwent either PVS or MUS after the FDA warning was issued in July 2011. Exclusion criteria included prior anti-incontinence surgery, concomitant surgery other than hysterectomy, and POP stage>2. Patients were followed prospectively with validated quality of life (QoL) questionnaires and subjective SEAPI (stress, emptying, anatomy, protection, inhibition) scores. Treatment success was defined as absence of subjective or objective SUI. Peri-operative complications were classified via the Clavien-Dindo scale. RESULTS Minimum follow-up was 12 months (mean 14.6). Ninety one (45%) and 110 (55%) women opted for PVS and MUS, respectively. Preoperative demographics and clinical parameters, including age, body mass index, parity, pad usage, mean abdominal leak point pressure, severity of concomitant POP, SEAPI scores, and mean QoL indices did not differ significantly between the groups. There was no difference in the proportion of women undergoing concomitant hysterectomy (52.7% vs. 50%, p=0.7). Treatment success was similar (75.8% vs. 80.9%, p=0.38) and there was no difference in rates of postoperative voiding dysfunction (1.1% vs. 1.8%, p=0.68) or de novo urgency incontinence (4.4% vs. 4.5%, p=0.96). Length of hospitalization did not significantly differ (1.18 vs. 1.16 days, p=0.9). There was no difference in the occurrence of Clavien-Dindo surgical complications between the two groups (6.6% vs. 10%, p=0.39). CONCLUSIONS Since the 2011 FDA warning, more women are forgoing the use of mesh in the treatment of SUI. In a contemporary cohort of women considered suitable candidates for either sling, both procedures offer comparable efficacy and complication rates. PVS may be safely offered to patients who would otherwise be good candidates for MUS if they are concerned with the implantation of mesh. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e344-e345 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Stephen Mock More articles by this author Jonathan Angelle More articles by this author W. Stuart Reynolds More articles by this author David J. Osborn More articles by this author Roger R. Dmochowski More articles by this author Alexander Gomelsky More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...